<DOC>
	<DOC>NCT02163161</DOC>
	<brief_summary>Phase 1, open label, single dose, 3 way crossover study to evaluate the bioavailability of a solid dose formulation of PF 04965842 relative to a suspension formulation under fasting conditions and the effect of food on the bioavailability of the solid dosage formulation of PF 04965842 in healthy subjects.</brief_summary>
	<brief_title>AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects and female subjects of non childbearing potential between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Subjects who received within 7 days prior to the first dose of study medication or are likely to receive during the study any moderate strong inhibitors of CYP3A4, eg, itraconazole, erythromycin, ketoconazole, protease inhibitors, verapamil, or diltiazem. Subjects who received within 28 days or are likely to receive during the study inducers of CYP3A4, eg rifampin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Open Label</keyword>
	<keyword>Single dose</keyword>
	<keyword>Crossover</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Fasting</keyword>
	<keyword>Fed</keyword>
	<keyword>PF-04965842</keyword>
	<keyword>Healthy</keyword>
</DOC>